Company facts
- Headquarters
- San Diego, California
- Most recent report
- 10-Q, filed Jul 30, 2026
- Incorporated
- Delaware
- Filings on record
- 1,000+ filings
- On EDGAR
- CIK 1093557
- Fiscal year ends
- December
- Filer status
- Large accelerated filer
Financials 8 of 31
News 8 of 93
Prospectuses and Registrations 8 of 16
- S-8 Registration statement for an employee plan May 9, 2025
- S-3ASR Automatic shelf registration Feb 18, 2025
- 424B5 Prospectus supplement for an offering Nov 22, 2021
- S-3ASR Automatic shelf registration Nov 22, 2021
- S-8 POS Post-effective amendment to an employee plan registration Feb 10, 2021
- S-8 POS Post-effective amendment to an employee plan registration Feb 10, 2021
- S-8 POS Post-effective amendment to an employee plan registration Feb 10, 2021
- S-8 POS Post-effective amendment to an employee plan registration Feb 10, 2021
Proxies 8 of 19
- DEFA14A Extra proxy material Apr 15, 2026
- DEF 14A Proxy statement for a shareholder vote Apr 15, 2026
- DEFA14A Extra proxy material May 2, 2025
- DEFA14A Extra proxy material Mar 27, 2025
- DEF 14A Proxy statement for a shareholder vote Mar 27, 2025
- DEF 14A Proxy statement for a shareholder vote Apr 22, 2024
- DEFA14A Extra proxy material Apr 6, 2023
- DEF 14A Proxy statement for a shareholder vote Apr 6, 2023
Ownership 8 of 823
- 4 Insider reported a trade Aug 28, 2026
- 144 Notice of a proposed sale of restricted stock Aug 27, 2026
- 4 Insider reported a trade Aug 25, 2026
- 4 Insider reported a trade Aug 25, 2026
- 4 Insider reported a trade Aug 25, 2026
- 4 Insider reported a trade Aug 25, 2026
- 4 Insider reported a trade Aug 24, 2026
- 144 Notice of a proposed sale of restricted stock Aug 20, 2026
Other 8 of 18
- SD Conflict minerals disclosure May 28, 2026
- ARS Annual report sent to shareholders Apr 15, 2026
- SD Conflict minerals disclosure May 29, 2025
- ARS Annual report sent to shareholders Mar 27, 2025
- SD Conflict minerals disclosure May 29, 2024
- ARS Annual report sent to shareholders Apr 22, 2024
- SD Conflict minerals disclosure May 31, 2023
- ARS Annual report sent to shareholders Apr 6, 2023
What to read: Jun 2026 10-Q
SECSift found 4 of 13 sections worth reading, with 0 positive, 12 notable, and 3 negative flags.
Financial Statements (Item 1)
Full financials with 13% revenue growth, 50% op income jump, sharp inventory reserve spike, and $600M buyback.NotableManagement's Discussion (Item 2)
Strong profit growth but operating cash fell; credit line maturing Oct 2026.Notable- Company expects to allocate at least 50% of operating cash flow (net of capex) to share repurchases long-term.
- Open purchase orders and contractual obligations totaled $1.42B as of June 30, 2026, most due within a year.
- A $41.2M acquisition in Q2 2026 increased cash used in investing activities.
- Heavy share repurchases in H1 2026: $603.6M more cash used than in H1 2025.
Legal Proceedings (Item 1)
Two securities class actions alive; one survived dismissal in part. G6/G7 product suits consolidated.Notable- Second securities class action filed October 2025; motion to dismiss filed June 2026; alleges G7 misstatements.
- Two new derivative actions filed March and April 2026; both stayed pending securities class action resolution.
- Six G6/G7 product class actions consolidated in federal court on May 15, 2026; motions for interim class counsel pending.
- State court G6/G7 class action remains stayed in favor of federal actions; joint status report due August 19, 2026.
Risk Factors (Item 1A)
New $1B buyback authorization and 8.6M shares repurchased in H1 2026.
What changed: Jun 2026 vs. Mar 2026
About 10% of DXCM's Jun 2026 10-Q is new information. 31 paragraphs were added, 102 changed, and 13 removed. Below are the most important lines SECSift identified.
New
Changed
Removed
Everything here comes from Dexcom Inc's own filings on SEC EDGAR. The filing list is rechecked every hour. SECSift analysis was completed on Aug 19, 2026, from the 10-Q for Jun 2026.